Novartis to invest in Israel's Gamida Cell, could buy out company

Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.

http://ift.tt/1sRANbc